Lysogene Announces Upcoming Presentations at the 2018 International MPS symposium
August 01, 2018 12:41 ET
|
Lysogene
CAMBRIDGE, Mass. and PARIS, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Lysogene (FR0013233475 – LYS), a pioneering biopharmaceutical company specializing in gene therapy targeting central nervous system...
Lysogene Reports Second Quarter Cash Position and Provides Business and Strategic Update
August 01, 2018 10:37 ET
|
Lysogene
CAMBRIDGE, Mass. and PARIS, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Lysogene (FR0013233475 – LYS), a pioneering biopharmaceutical company specializing in gene therapy targeting central nervous system...
Lysogene Announces the Nomination of Dr. Ralph Laufer as Chief Scientific Officer and Member of the Executive Team
May 15, 2018 11:45 ET
|
Lysogene
CAMBRIDGE, Mass. and PARIS, May 15, 2018 (GLOBE NEWSWIRE) -- Lysogene (FR0013233475 – LYS), a pioneering biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS)...
Lysogene Signs Partnership Agreement with Dr. Hervé Moine, Researcher at the IGBMC(1) and the SATT(2) Conectus Alsace, in the Fragile X Syndrome
April 24, 2018 02:00 ET
|
Lysogene
Development of a gene therapy product for the treatment of patients with Fragile X syndromeImplementation of the project through a unique partnershipFirst results anticipated in 2019 ...
Lysogene Strengthens Board of Directors with Appointment of Dr. Peter Lichtlen
April 23, 2018 02:00 ET
|
Lysogene
CAMBRIDGE, Mass. and PARIS, April 23, 2018 (GLOBE NEWSWIRE) -- Lysogene (FR0013233475 – LYS), a leading biopharmaceutical company pioneering gene therapy technologies to treat central nervous system...
Lysogene Reports First Quarter Financial Results and Provides Business Update
April 16, 2018 01:45 ET
|
Lysogene
Extended CNS pipeline with a collaboration agreement for the development of an AAV-based gene therapy for Fragile X syndrome, the most common single gene cause of autism, a condition of high unmet...
Lysogene Announces Company Presentations at October & November Investor Conferences
October 04, 2017 04:00 ET
|
Lysogene
PARIS and CAMBRIDGE, Mass., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Lysogene (FR0013233475 – LYS) (LYS.PA), a leading, biopharmaceutical company pioneering gene therapy technologies to treat central...
Lysogene Appoints David Schilansky to Board of Directors
December 07, 2016 07:00 ET
|
Lysogene
PARIS, Dec. 07, 2016 (GLOBE NEWSWIRE) -- Lysogene, a biopharmaceutical company specializing in gene therapy for rare central nervous system diseases, appointed David Schilansky to the board of...